News
- Their objective is to help these drugs move from pre-clinical stage to clinical use
- The project, led by the University of Barcelona and Ferrer, counts on a €2.8 million budget, and is formed by eighteen firms and entities
Bioiberica presents the beneficial effects of Mobilee and B2cool in an international pharmaceutical congress
The presentation took place during the workshop of the Muscletech Network held in the Camp Nou in early October
The aim of these lectures is to create a network of international awareness and support for research in prevention, diagnosis and treatment of muscle and tendon injuries
- This is the main conclusion of a new clinical trial involving more than 600 patients from 5 European countries which will be presented tomorrow at the BMJD congress
These biomarkers have been proved to have potential for monitoring the treatment of that disease, and are related with an improvement in inflammation and renal damage
Bioiberica has recently completed a test with dogs suffering from leishmaniasis that had been treated with Impromune®, a product based on nucleotides and AHCC, which showed better results than the standard treatment